cbdMD (YCBD) Other Non-Current Liabilities (2018 - 2023)
cbdMD (YCBD) reported Other Non-Current Liabilities of $20611.0 for Q4 2023, down 87.2% on a YoY basis from $161000.0 in Q4 2022, and down 77.19% sequentially from $90363.0 in Q3 2023.
cbdMD (YCBD) Other Non-Current Liabilities (2018 - 2023) Analysis & Trends
cbdMD (YCBD) has 6 years of Other Non-Current Liabilities data on file, last reported at $20611.0 in Q4 2023.
- For the quarter ending Q4 2023, Other Non-Current Liabilities fell 87.2% year-over-year to $20611.0; the trailing twelve-month figure through Dec 2023 stood at $20611.0 (down 87.2% YoY), and the FY2023 full-year result was $90363.0, down 67.26% from the prior year.
- Other Non-Current Liabilities slipped to $20611.0 in Q4 2023, from $90363.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $102.3 million in Q1 2019 to a low of $13000.0 in Q1 2022.
- A 5-year average of $15.8 million and a median of $276000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slumped 99.94% in 2022 and surged 1184.62% in 2023, its largest moves.
- Tracing YCBD's Other Non-Current Liabilities over 5 years: stood at $33.7 million in 2019, then slumped by 51.93% to $16.2 million in 2020, then plunged by 99.01% to $161000.0 in 2021, then changed by 0.0% to $161000.0 in 2022, then tumbled by 87.2% to $20611.0 in 2023.
- Business Quant data shows YCBD's Other Non-Current Liabilities at $20611.0 in Q4 2023, $90363.0 in Q3 2023, and $122230.0 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | cbdMD | 438,678.80 | -2.95 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 20,611.00 |
| Sep 30, 2023 | 90,363.00 |
| Jun 30, 2023 | 122,230.00 |
| Mar 31, 2023 | 167,000.00 |
| Dec 31, 2022 | 161,000.00 |
| Sep 30, 2022 | 276,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | 161,000.00 |
| Sep 30, 2021 | 9.86 Mn |
| Jun 30, 2021 | 920,000.00 |
| Mar 31, 2021 | 22.30 Mn |
| Sep 30, 2020 | 16.20 Mn |
| Dec 31, 2019 | 33.70 Mn |
| Sep 30, 2019 | 50.60 Mn |
| Mar 31, 2019 | 102.27 Mn |
| Dec 31, 2018 | 71.35 Mn |
| Jun 30, 2018 | 8,004.00 |